HEV in Blood Donors in Switzerland: The Route to Safe Blood Products

Overview

Journal Pathogens

Date 2024 Oct 25

PMID 39452782

Authors

Mauro Serricchio

Peter Gowland

Nadja Widmer

Martin Stolz

Christoph Niederhauser

Affiliations

Soon will be listed here.

Abstract

The hepatitis E virus (HEV) is an emerging infectious disease with zoonotic potential, causing acute hepatitis in humans. Infections in healthy individuals are often acute, self-limiting and asymptomatic, thus leading to the underdiagnosis of HEV infections. Asymptomatic HEV infections pose a problem for blood transfusion safety by increasing the risk for transfusion-transmitted HEV infections. Here, we describe the journey from determining the HEV seroprevalence among blood donors to the implementation of routine HEV RNA testing of all blood products in Switzerland in 2018 and summarise the HEV cases detected since. In total, 290 HEV-positive blood donations were detected by mini-pool nucleic acid testing (NAT) in Switzerland in the period of October 2018-December 2023, equal to an incidence of 20.7 per 100,000 donations. Thanks to the implemented scheme, no transfusion-transmitted infections occurred in this period. Furthermore, blood donation monitoring has proven to be an effective means of detecting HEV outbreaks in the general population. HEV cases in Swiss blood donors are caused by two major genotypes, the Swiss-endemic subtypes 3h3 and 3c. Interestingly, 11 HEV cases (5%) were of genotype 3ra, a variant found in wild and farmed rabbits. Our results indicate that mini-pool NAT is an efficient method to reduce the risk of transfusion-transmitted HEV infections.

References

Sauleda S, Ong E, Bes M, Janssen A, Cory R, Babizki M . Seroprevalence of hepatitis E virus (HEV) and detection of HEV RNA with a transcription-mediated amplification assay in blood donors from Catalonia (Spain). Transfusion. 2014; 55(5):972-9. DOI: 10.1111/trf.12929. View

Khuroo M . Study of an epidemic of non-A, non-B hepatitis. Possibility of another human hepatitis virus distinct from post-transfusion non-A, non-B type. Am J Med. 1980; 68(6):818-24. DOI: 10.1016/0002-9343(80)90200-4. View

Mooij S, Hogema B, Tulen A, van Pelt W, Franz E, Zaaijer H . Risk factors for hepatitis E virus seropositivity in Dutch blood donors. BMC Infect Dis. 2018; 18(1):173. PMC: 5899381. DOI: 10.1186/s12879-018-3078-9. View

Fontana S, Ripellino P, Niederhauser C, Widmer N, Gowland P, Petrini O . Epidemiology of HEV Infection in Blood Donors in Southern Switzerland. Microorganisms. 2023; 11(10). PMC: 10609445. DOI: 10.3390/microorganisms11102375. View

Hewitt P, Ijaz S, Brailsford S, Brett R, Dicks S, Haywood B . Hepatitis E virus in blood components: a prevalence and transmission study in southeast England. Lancet. 2014; 384(9956):1766-73. DOI: 10.1016/S0140-6736(14)61034-5. View

Wenzel J, Preiss J, Schemmerer M, Huber B, Jilg W . Test performance characteristics of Anti-HEV IgG assays strongly influence hepatitis E seroprevalence estimates. J Infect Dis. 2012; 207(3):497-500. DOI: 10.1093/infdis/jis688. View

Songtanin B, Molehin A, Brittan K, Manatsathit W, Nugent K . Hepatitis E Virus Infections: Epidemiology, Genetic Diversity, and Clinical Considerations. Viruses. 2023; 15(6). PMC: 10304420. DOI: 10.3390/v15061389. View

Perez-Gracia M, Garcia M, Suay B, Mateos-Lindemann M . Current Knowledge on Hepatitis E. J Clin Transl Hepatol. 2015; 3(2):117-26. PMC: 4548356. DOI: 10.14218/JCTH.2015.00009. View

Grabarczyk P, Sulkowska E, Gdowska J, Kopacz A, Liszewski G, Kubicka-Russel D . Molecular and serological infection marker screening in blood donors indicates high endemicity of hepatitis E virus in Poland. Transfusion. 2018; 58(5):1245-1253. DOI: 10.1111/trf.14531. View

10.

Mallet V, Sberro-Soussan R, Vallet-Pichard A, Roque-Afonso A, Pol S . Transmission of Hepatitis E Virus by Plasma Exchange: A Case Report. Ann Intern Med. 2016; 164(12):851-2. DOI: 10.7326/L15-0502. View

11.

Cleland A, Smith L, Crossan C, Blatchford O, Dalton H, Scobie L . Hepatitis E virus in Scottish blood donors. Vox Sang. 2013; 105(4):283-9. DOI: 10.1111/vox.12056. View

12.

Holm D, Moessner B, Engle R, Zaaijer H, Georgsen J, Purcell R . Declining prevalence of hepatitis E antibodies among Danish blood donors. Transfusion. 2015; 55(7):1662-7. DOI: 10.1111/trf.13028. View

13.

Cordes A, Goudeva L, Lutgehetmann M, Wenzel J, Behrendt P, Wedemeyer H . Risk of transfusion-transmitted hepatitis E virus infection from pool-tested platelets and plasma. J Hepatol. 2021; 76(1):46-52. DOI: 10.1016/j.jhep.2021.08.018. View

14.

Kumar S, Stecher G, Li M, Knyaz C, Tamura K . MEGA X: Molecular Evolutionary Genetics Analysis across Computing Platforms. Mol Biol Evol. 2018; 35(6):1547-1549. PMC: 5967553. DOI: 10.1093/molbev/msy096. View

15.

Vonlanthen-Specker I, Stephan R, Sidler X, Moor D, Fraefel C, Bachofen C . Genetic Diversity of Hepatitis E Virus Type 3 in Switzerland-From Stable to Table. Animals (Basel). 2021; 11(11). PMC: 8614342. DOI: 10.3390/ani11113177. View

16.

Niederhauser C, Gowland P, Widmer N, El Dusouqui S, Mattle-Greminger M, Gottschalk J . Prevalence of Acute Hepatitis E Virus Infections in Swiss Blood Donors 2018-2020. Viruses. 2024; 16(5). PMC: 11125967. DOI: 10.3390/v16050744. View

17.

Kamar N, Izopet J, Pavio N, Aggarwal R, Labrique A, Wedemeyer H . Hepatitis E virus infection. Nat Rev Dis Primers. 2017; 3:17086. DOI: 10.1038/nrdp.2017.86. View

18.

Vollmer T, Diekmann J, Johne R, Eberhardt M, Knabbe C, Dreier J . Novel approach for detection of hepatitis E virus infection in German blood donors. J Clin Microbiol. 2012; 50(8):2708-13. PMC: 3421526. DOI: 10.1128/JCM.01119-12. View

19.

Slot E, Hogema B, Riezebos-Brilman A, Kok T, Molier M, Zaaijer H . Silent hepatitis E virus infection in Dutch blood donors, 2011 to 2012. Euro Surveill. 2013; 18(31). DOI: 10.2807/1560-7917.es2013.18.31.20550. View

20.

Gorski I, Babic I, Bingulac-Popovic J, Topic-Sestan P, Jagnjic S, Jemersic L . Prevalence of HEV RNA in Croatian blood donors. Transfus Clin Biol. 2023; 30(2):244-248. DOI: 10.1016/j.tracli.2023.01.005. View